Optaflu vaccine suspension for injection 0.5ml pre-filled syringes United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

optaflu vaccine suspension for injection 0.5ml pre-filled syringes

seqirus vaccines ltd - influenza virus surface antigens - suspension for injection

Zoonotic Influenza Vaccine Seqirus European Union - English - EMA (European Medicines Agency)

zoonotic influenza vaccine seqirus

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vaccines - active immunisation against h5 subtype of influenza a virus

INFLUVAC TETRA influenza virus haemagglutinin 0.5mL vaccine prefilled syringe with 16 mm needle, 2024 Australia - English - Department of Health (Therapeutic Goods Administration)

influvac tetra influenza virus haemagglutinin 0.5ml vaccine prefilled syringe with 16 mm needle, 2024

viatris pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - suspension - excipient ingredients: magnesium chloride hexahydrate; monobasic potassium phosphate; dibasic sodium phosphate dihydrate; water for injections; potassium chloride; calcium chloride dihydrate; sodium chloride - for the prevention of influenza caused by influenza virus, types a and b.,for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.,influvac tetra is indicated in adults and children from 6 months of age and older.

VAXIGRIP TETRA Inactivated Quadrivalent Influenza Vaccine (Split Virion) influenza virus haemagglutinin 60 mcg 0.5 mL suspension Australia - English - Department of Health (Therapeutic Goods Administration)

vaxigrip tetra inactivated quadrivalent influenza vaccine (split virion) influenza virus haemagglutinin 60 mcg 0.5 ml suspension

sanofi-aventis australia pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: sodium chloride; water for injections; potassium chloride; monobasic potassium phosphate; dibasic sodium phosphate dihydrate - vaxigrip tetra is indicated for the prevention of influenza disease caused by the two influenza a virus subtypes and the two influenza b virus types contained in the vaccine for:,- active immunisation of adults, including pregnant women, and children from 6 months of age and older,- passive protection of infant(s) from birth to less than 6 months of age following vaccination of pregnant women (see sections 4.2 dose and method of administration, 4.4 special warnings and precautions for use, 4.6 fertility, pregnancy and lactation and 5.1 pharmacodynamic properties ? clinical trials).

VAXIGRIP TETRA Inactivated Quadrivalent Influenza Vaccine (Split Virion) influenza virus haemagglutinin 60 mcg 0.5 mL suspension for injection in pre-filled syringe needle free 2024 Season Australia - English - Department of Health (Therapeutic Goods Administration)

vaxigrip tetra inactivated quadrivalent influenza vaccine (split virion) influenza virus haemagglutinin 60 mcg 0.5 ml suspension for injection in pre-filled syringe needle free 2024 season

sanofi-aventis australia pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: sodium chloride; water for injections; potassium chloride; monobasic potassium phosphate; dibasic sodium phosphate dihydrate - vaxigrip tetra is indicated for the prevention of influenza disease caused by the two influenza a virus subtypes and the two influenza b virus types contained in the vaccine for:,- active immunisation of adults, including pregnant women, and children from 6 months of age and older,- passive protection of infant(s) from birth to less than 6 months of age following vaccination of pregnant women (see sections 4.2 dose and method of administration, 4.4 special warnings and precautions for use, 4.6 fertility, pregnancy and lactation and 5.1 pharmacodynamic properties ? clinical trials).

Fluad Tetra European Union - English - EMA (European Medicines Agency)

fluad tetra

seqirus netherlands b.v. - a/darwin/9/2021 (h3n2) - like strain (a/darwin/6/2021, ivr-227) / a/victoria/4897/2022 (h1n1) pdm09-like strain (a/victoria/4897/2022, ivr-238) / b/phuket/3073/2013-like strain (b/phuket/3073/2013, bvr-1b) / influenza virus b/austria/1359417/2021-like strain (b/austria/1359417/2021, bvr-26) - influenza, human - vaccines - prophylaxis of influenza in the elderly (65 years of age and older).fluad tetra should be used in accordance with official recommendations.

Aflunov(r) Prepandemic Influenza Vaccine, H5N1 (surface antigen, inactivated, adjuvanted) 0.5mL pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

aflunov(r) prepandemic influenza vaccine, h5n1 (surface antigen, inactivated, adjuvanted) 0.5ml pre-filled syringe

seqirus pty ltd - influenza virus haemagglutinin -

INFLUVAC inactivated influenza 0.5 mL vaccine long syringe with 16 mm needle 2017 Australia - English - Department of Health (Therapeutic Goods Administration)

influvac inactivated influenza 0.5 ml vaccine long syringe with 16 mm needle 2017

mylan health pty ltd - influenza virus haemagglutinin -

FLUARIX TETRA inactivated split influenza vaccine suspension for injection 0.5 mL pre-filled syringe without needle, SH2024 influenza season Australia - English - Department of Health (Therapeutic Goods Administration)

fluarix tetra inactivated split influenza vaccine suspension for injection 0.5 ml pre-filled syringe without needle, sh2024 influenza season

glaxosmithkline australia pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: dl-alpha-tocopheryl acid succinate; potassium chloride; sodium chloride; water for injections; polysorbate 80; dibasic sodium phosphate dodecahydrate; magnesium chloride hexahydrate; octoxinol 10; monobasic potassium phosphate - fluarix tetra is a quadrivalent vaccine indicated for active immunisation of adults and children from 6 months of age for the prevention of influenza disease caused by the influenza virus types a and b contained in the vaccine (see section 5.1 pharmacodynamic properties, clinical trials).,the use of fluarix tetra should be based on official recommendations.

INFLUENZA A (H1N1) 2009 MONOVALENT VACCINE- influenza a virus a/california/7/2009(h1n1)-like antigen (formaldehyde inactivated) United States - English - NLM (National Library of Medicine)

influenza a (h1n1) 2009 monovalent vaccine- influenza a virus a/california/7/2009(h1n1)-like antigen (formaldehyde inactivated)

sanofi pasteur inc. - influenza a virus a/california/7/2009(h1n1)-like antigen (formaldehyde inactivated) (unii: 5i5hvc73i8) (influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (formaldehyde inactivated) - unii:euj84un96z) - influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (formaldehyde inactivated) 15 ug in 0.5 ml - influenza a (h1n1) 2009 monovalent vaccine is an inactivated influenza virus vaccine indicated for active immunization of persons 6 months of age and older against influenza disease caused by pandemic (h1n1) 2009 virus. do not administer influenza a (h1n1) 2009 monovalent vaccine to anyone with a known severe hypersensitivity to egg proteins or any component of the vaccine or life-threatening reactions after previous administration of any influenza vaccine. [see warnings and precautions (5) and description (11) ] sanofi pasteur's influenza a (h1n1) 2009 monovalent vaccine and seasonal trivalent influenza virus vaccine (fluzone vaccine) are manufactured by the same process. available information for fluzone vaccine is provided in this section. pregnancy category c: animal reproduction studies have not been conducted with influenza a (h1n1) 2009 monovalent vaccine or fluzone vaccine. it is also not known whether these vaccines can cause fetal harm when administered to a pregnant woman or can affect reproduction